Bioanalytical immunoassay services for biosimilar development
Unique bioanalytic capabilities to accelerate biosimilar studies
Biosimilars are increasingly vital in the expanding global biotech market. Achieving regulatory approval requires demonstrating comparable safety and efficacy to approved biological products. The complexity of biosimilar molecules adds unique challenges during development and manufacturing.
Successfully navigating these challenges demands an experienced partner. IQVIA Laboratories offers tailored solutions to help you make informed decisions and achieve validated outcomes throughout your study, from research to commercialization.
Our immunoassay services specialize in developing, transferring, and validating non-clinical and clinical assays crucial for biosimilar studies, including quantitative, immunogenicity, and biomarker assays. We excel in:
-
Pharmacokinetic (PK) concentration assays: Developing or transferring quantitative immunoassays efficiently to demonstrate bioanalytical similarity between originator and biosimilar drugs.
-
Anti-drug antibody (ADA) assays: Optimizing assays to demonstrate ADA binding comparability, addressing sensitivity and free drug tolerance with advanced techniques.
-
Neutralizing antibody (NAb) assays: Tailoring plate-based competitive ligand binding or cell-based approaches specific to your drug’s mode of action.
Our Project Managers, all scientists with hands-on bioanalytical expertise, act as trusted partners throughout your project. They provide regular updates, practical advice, and proactive issue resolution to ensure smooth assay operations.
Integrated within our bioanalytical laboratories and central facilities, our workflow ensures efficiency and flexibility across the product development cycle. IQVIA Laboratories has a proven track record, having developed and tested thousands of biosimilar and comparator samples across various therapeutic areas, including:
- Adalimumab
- Nivolumab
- Pembrolizumab
- Ipilimumab
- Omalizumab
- Rituximab
Whether you need high-throughput assay development or guidance through regulatory complexities, our team is ready to collaborate at every step. Quality is paramount in our bioanalytical lifecycle, from method development to final sample testing reports.
Contact us today to discuss how we can streamline timelines and enhance the success potential of your biosimilar product.
Related Services
Bioanalytical Services
Learn moreIn Vitro Screening
Learn moreDiscovery Bioanalysis
Learn moreSmall and Large Molecule LC-MS
Learn moreQuantitative Assays for Peptides using LC-MS
Learn moreBiotherapeutic Immunoassay Services
Learn moreImmunoassay and Immunogenicity
Learn moreBioanalytical Immunoassay Services for Biosimilar Development
Learn moreValidated Assays
Learn moreImmune Landscape Signatures
Learn moreRelated Insights
Managing Informed Consent Samples from Clinical Trials
A set of best practices for the definition, tracking and management of allowable use attributes associated with samples collected in protocol based clinical trials
Biorepository and Specimen Management
Your biological specimens are irreplaceable assets – trust them with a proven partner
ADME Services
Accelerating your drug discovery, preclinical and clinical programs
IQVIA Laboratories Central Laboratory Services
Central laboratory solutions supporting clinical trials around the world
Helping you master your lab data
Improved oversight with your lab data now in full view
NASH and Liver Disease Capabilities
Nonalcoholic Fatty Liver Diseases & Non-alcoholic Steatohepatitis (NAFLD & NASH)
How COVID-19 Changed Clinical Trial Dynamics and Environment
Precision Medicine World Conference 2021 Virtual Presentation
Pediatric Initiative
Optimizing small blood volumes to prevent canceled tests in clinical trials for pediatric patients
Vaccine Laboratory Services
Test Menu
SARS-CoV-2 Vaccine Induced Antibody Profiles
Presented at World Vaccine Congress 2021